|

Toxicity of Intensive First-Line Treatment for Adult Burkitt Lymphoma: A Retrospective Observational Study

RECRUITINGSponsored by University Hospital, Strasbourg, France
Actively Recruiting
SponsorUniversity Hospital, Strasbourg, France
Started2026-02-11
Est. completion2027-02-11
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

Burkitt lymphoma is a rare, highly aggressive B-cell non-Hodgkin lymphoma in adults. Although intensive multi-agent chemotherapy can achieve high complete remission rates, it is associated with substantial toxicity, morbidity, and sometimes treatment-related mortality. This retrospective, single-center observational study aims to characterize the short- and long-term complications of intensive first-line treatment in adults with Burkitt lymphoma managed at Strasbourg University Hospitals. The study will evaluate treatment-related toxicities, overall survival at five years, and progression-free survival at 24 months. Secondary objectives include assessing treatment delays, chemotherapy dose reductions, and their associations with toxicity, disease location at diagnosis, and survival. All eligible adult patients diagnosed with Burkitt lymphoma or managed for this condition at Strasbourg University Hospitals and the ICANS between January 1, 2009, and December 31, 2025, will be considered. The study will use retrospective medical record data, with no a priori sample size calculation because of the rarity of the disease and the single-center design.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Adults aged 18 years or older.
* Patients diagnosed with Burkitt lymphoma at Strasbourg University Hospitals between January 1, 2009, and December 31, 2025, and/or managed by the Hematology Department of Strasbourg University Hospitals or ICANS for Burkitt lymphoma during this period.
* No written objection documented in the medical record to the reuse of personal data for scientific research.

Exclusion Criteria:

* Patients who have objected to the reuse of their personal data for scientific research.
* Patients diagnosed with another B-cell non-Hodgkin lymphoma other than Burkitt lymphoma.
* Patients for whom accessible data are unavailable.
* Individuals under legal protection (sauvegarde de justice).
* Individuals under guardianship or curatorship (tutelle or curatelle).

Conditions4

Adult Burkitt LymphomaCancerChemotherapy-Related ToxicityOverall and Progression-Free Survival

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.